Engineered immune cells take aim at returning blood cancers
NCT ID NCT01430390
First seen Jun 14, 2026 · Last updated Jun 21, 2026 · Updated 3 times
Summary
This early-phase trial tests the safety of giving specially modified T-cells from a donor to people with B-cell leukemia or lymphoma that has returned after a stem cell or organ transplant. The modified cells are designed to target a protein called CD19 on cancer cells. Only 19 participants are enrolled, and the main goal is to check for side effects, not to cure the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LYMPHOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Genetically modified donor T-cells (EBV-CTLs targeting CD19)
What this could lead to
If it works, this could point toward a new way to treat B-cell cancers that return after a stem cell or organ transplant.
What could go wrong
This is a very early, small phase 1 trial focused on safety, not effectiveness. The modified cells may not survive or control the cancer, and there are risks like graft-versus-host disease.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.